Arbutus Biopharma Corp ABUS
Arbutus Biopharma Corp (Nasdaq: ABUS) is an infectious disease drug developer. Its lead program, imdusiran (AB-729), is in Phase 2 for chronic hepatitis B. Its next catalyst on record is imdusiran: Phase 2b trial initiation (FDA alignment reached May 2026) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: imdusiran — Phase 2b trial initiation (FDA alignment reached May 2026) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| imdusiran | chronic hepatitis B | RNA (siRNA/ASO/mRNA) | Phase 2 |
| AB-101 | oncology/HBV (oral PD-L1 inhibitor) | small molecule | Phase 1 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 infectious disease companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.